Get started
Author

Reed Masakayan

ORCID: 0000-0003-3591-8869
Observed ORCID: 0000-0003-3591-8869
OpenAlex ID: A5005178144
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
2019 · Eric L. Smith, Kim Harrington, et al. · Science Translational Medicine · 402
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
2018 · Eric L. Smith, Mette Staehr, et al. · Molecular Therapy · 119
PDF
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome
2024 · Terese C. Hammond, Marco A. Purbhoo, et al. · Nature Communications · 48
PDF
CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma
2018 · Eric L. Smith, Kimberly Harrington, et al. · Blood · 17
Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM
2017 · Eric L Smith, Sham Mailankody, et al. · Blood · 16
Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma
2017 · Kim Harrington, Rebecca Wu, et al. · University of Southern Denmark Research Portal (University of Southern Denmark) · 10
The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2025 · Eleni Chantzoura, Efrat Altman-Sharoni, et al. · Cancer Immunology Research · 5
322 MiNK-413: a next generation armored allogenic BCMA CAR iNKT product
2022 · Eleni Chantzoura, Efrat Altman Sharoni, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
358 Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment
2022 · Xavier Michelet, Martyna Popis, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
372 agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment
2022 · Sapana Pokharel, John Chamberland, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
2026 · Shanmugarajan Krishnan, Bishnu Joshi, et al. · Journal for ImmunoTherapy of Cancer
PDF
Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy
2026 · Terese C. Hammond, Marco A Purbhoo, et al. · Clinical Immunology Communications
Data from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S1 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S6 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Table S3 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S5 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S8 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S4 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Table S1 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Table S2 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S2 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S3 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Figure S7 from The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
2026 · Eleni Chantzoura, Efrat Altman-Sharoni, et al.
Investigation of the effect of hypoxia and adenosine on the effector functions of invariant natural killer T Cells for immunotherapy
2025 · Reed Masakayan · Digital Repository Service (Northeastern University)
Works count: 25
Citation count: 622
H-index: 6
I10-index: 6
Year
Topic
Type